TLR4+CXCR4+ plasma cells drive nephritis development in systemic lupus erythematosus

Objectives In patients with systemic lupus erythematosus (SLE), immune tolerance breakdown leads to autoantibody production and immune-complex glomerulonephritis. This study aimed to identify pathogenic plasma cells (PC) in the development of lupus nephritis. Methods PC subsets in peripheral blood and renal tissue of patients with SLE and lupus mice were examined by flow cytometry and confocal microscopy, respectively. Sorting-purified PCs from lupus mice were adoptively transferred into Rag2-deficient recipients, in which immune-complex deposition and renal pathology were investigated. In culture, PCs from lupus mice and patients with SLE were treated with a TLR4 inhibitor and examined for autoantibody secretion by enzyme-linked immunospot assay (ELISPOT). Moreover, lupus mice were treated with a TLR4 inhibitor, followed by the assessment of serum autoantibody levels and glomerulonephritis activity. Results The frequencies of TLR4+CXCR4+ PCs in peripheral blood and renal tissue were found significantly increased with the potent production of anti-dsDNA IgG, which were associated with severe renal damages in patients with SLE and mice with experimental lupus. Adoptive transfer of TLR4+CXCR4+ PCs from lupus mice led to autoantibody production and glomerulonephritis development in Rag2-deficient recipients. In culture, TLR4+CXCR4+ PCs from both lupus mice and patients with SLE showed markedly reduced anti-dsDNA IgG secretion on TLR4 blockade. Moreover, in vivo treatment with TLR4 inhibitor significantly attenuated autoantibody production and renal damages in lupus mice. Conclusions These findings demonstrate a pathogenic role of TLR4+CXCR4+ PCs in the development of lupus nephritis and may provide new therapeutic strategies for the treatment of SLE.

[1]  Q. Lu,et al.  Epigenetic regulation in B-cell maturation and its dysregulation in autoimmunity , 2018, Cellular & Molecular Immunology.

[2]  E. Ballestar,et al.  New insights into the epigenetics of inflammatory rheumatic diseases , 2017, Nature Reviews Rheumatology.

[3]  M. Gallieni,et al.  Lupus nephritis and B-cell targeting therapy , 2017, Expert review of clinical immunology.

[4]  Jie Tian,et al.  Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sjögren’s syndrome , 2017, Cellular & Molecular Immunology.

[5]  P. Emery,et al.  Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition , 2017, The Journal of Immunology.

[6]  Jeff E. Mold,et al.  Antibody-secreting plasma cells persist for decades in human intestine , 2017, The Journal of experimental medicine.

[7]  Andreas Radbruch,et al.  Plasma cells as an innovative target in autoimmune disease with renal manifestations , 2016, Nature Reviews Nephrology.

[8]  Ivan V. Gregoretti,et al.  Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. , 2015, Immunity.

[9]  Ivan V. Gregoretti,et al.  Diversity, cellular origin and autoreactivity of antibody-secreting cell expansions in acute Systemic Lupus Erythematosus , 2015, Nature Immunology.

[10]  J. Grün,et al.  A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. , 2015, Blood.

[11]  Andreas Radbruch,et al.  The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus , 2015, Annals of the rheumatic diseases.

[12]  F. Berberich-Siebelt,et al.  Follicular regulatory T cells control humoral autoimmunity via NFAT2-regulated CXCR5 expression , 2014, The Journal of experimental medicine.

[13]  A. Radbruch,et al.  Autoantibodies from long-lived ‘memory’ plasma cells of NZB/W mice drive immune complex nephritis , 2013, Annals of the rheumatic diseases.

[14]  Yuzhang Wu,et al.  The role of microRNAs in B-cell development and function , 2013, Cellular and Molecular Immunology.

[15]  S. Stowell,et al.  Initiation and Regulation of Complement during Hemolytic Transfusion Reactions , 2012, Clinical & developmental immunology.

[16]  Gerald McGwin,et al.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[17]  Yu-cheng Yan,et al.  Association of Intrarenal B-Cell Infiltrates with Clinical Outcome in Lupus Nephritis: A Study of 192 Cases , 2012, Clinical & developmental immunology.

[18]  B. Robinson,et al.  Programmed Death Ligand 2 in Cancer-Induced Immune Suppression , 2012, Clinical & developmental immunology.

[19]  U. Andersson,et al.  HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease , 2012, Nature Reviews Rheumatology.

[20]  T. Winkler,et al.  High frequency of autoantibody‐secreting cells and long‐lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice , 2011, European journal of immunology.

[21]  Kenneth G. C. Smith,et al.  Local renal autoantibody production in lupus nephritis. , 2011, Journal of the American Society of Nephrology : JASN.

[22]  S. Akira,et al.  TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. , 2010, Journal of autoimmunity.

[23]  S. Chadban,et al.  HMGB1 contributes to kidney ischemia reperfusion injury. , 2010, Journal of the American Society of Nephrology : JASN.

[24]  Y. Rong,et al.  TLR4 Activation Is Required for IL-17–Induced Multiple Tissue Inflammation and Wasting in Mice , 2010, The Journal of Immunology.

[25]  M. Tinguely,et al.  Plasma cell toll‐like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production , 2009, Immunology.

[26]  C. Arnoult,et al.  Critical Role of TLR2 and TLR4 in Autoantibody Production and Glomerulonephritis in lpr Mutation-Induced Mouse Lupus1 , 2009, The Journal of Immunology.

[27]  P. Igarashi,et al.  CXCR4/CXCL12 Hyperexpression Plays a Pivotal Role in the Pathogenesis of Lupus1 , 2009, The Journal of Immunology.

[28]  Andreas Radbruch,et al.  HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus , 2009, Annals of the rheumatic diseases.

[29]  M. Bianchi,et al.  Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE , 2008, The Journal of experimental medicine.

[30]  Kerstin Amann,et al.  The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis , 2008, Nature Medicine.

[31]  W. Yeh,et al.  LPS/TLR4 signal transduction pathway. , 2008, Cytokine.

[32]  R. Medzhitov,et al.  TLR4 Up-Regulation at Protein or Gene Level Is Pathogenic for Lupus-Like Autoimmune Disease1 , 2006, The Journal of Immunology.

[33]  C. Tsatsanis,et al.  Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. , 2006, Arthritis and rheumatism.

[34]  Irun R. Cohen,et al.  Heat Shock Protein 60 Activates B Cells via the TLR4-MyD88 Pathway1 , 2005, The Journal of Immunology.

[35]  S. Xiong,et al.  Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. , 2005, Rheumatology.

[36]  V. Pascual,et al.  Defective B cell tolerance checkpoints in systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[37]  K. Calame,et al.  Regulation of plasma-cell development , 2005, Nature Reviews Immunology.

[38]  Y. Shoenfeld,et al.  Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. , 2004, Seminars in arthritis and rheumatism.

[39]  Hong Li,et al.  Induction of systemic lupus erythematosus syndrome in BALB/c mice by immunization with active chromatin. , 2004, Acta pharmacologica Sinica.

[40]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[41]  P. Lipsky,et al.  Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus1 , 2000, The Journal of Immunology.

[42]  J. Goust,et al.  Systemic lupus erythematosus. , 1976, Immunology series.

[43]  C. Gordon,et al.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. , 2010, Arthritis and rheumatism.